In vivo experiments in a mouse model of MPN confirmed the efficacy of HSP90 targeting because treatment with the HSP90 inhibitor PU-H71 resulted in significant reductions in disease parameters and better chances of survival [49]. This evidence concerns the gene HSP90AA1 and myeloproliferative disorder.